Telaprevir and Cariprazine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Telaprevir
No brand names on recordCariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Telaprevir is a strong blocker of a liver enzyme called CYP3A4, which is the same enzyme your body uses to break down cariprazine (Vraylar). When telaprevir slows that enzyme down, cariprazine and its long-lasting active form can build up in your body. That can mean stronger side effects, like restlessness, drowsiness, muscle stiffness, or feeling shaky.
The good news is this is very manageable. Your care team already knows to use a lower, less frequent cariprazine dose when it is paired with a strong blocker like telaprevir. Please don't change anything on your own. Just make sure both your pharmacist and prescriber know you take both, and they will tailor your dose and keep an eye on how you feel.
Mechanism: Telaprevir is a strong CYP3A4 inhibitor. Cariprazine is a CYP3A4 substrate; the enzyme also forms and clears its active metabolite, didesmethylcariprazine. Inhibition raises exposure (AUC/Cmax) of both parent drug and active metabolite, increasing dopaminergic adverse effects (akathisia, EPS, somnolence). Neither agent is a prodrug in a way that reverses this.
Evidence: theoretical; severity: major; onset unspecified.
Management (per labeling):
- Schizophrenia/bipolar mania, initiating on inhibitor: 1.5 mg every 3 days, up to 1.5 mg every other day per response.
- Bipolar depression/adjunct MDD: 1.5 mg every 3 days.
- Adding inhibitor to stable 1.5-3 mg/day: reduce to 1.5 mg every 3 days; on 4.5-6 mg/day: 1.5 mg every other day.
- On inhibitor discontinuation, re-titrate upward. Monitor for EPS/sedation.
What happens
Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine
Interaction Deep Dive
Giving cariprazine (a CYP3A4 substrate) together with a strong CYP3A4 inhibitor can raise the exposure of cariprazine as well as its active metabolite, didesmethylcariprazine. If cariprazine is being started in a patient already receiving a strong CYP3A4 inhibitor (for schizophrenia or bipolar mania), begin dosing at 1.5 mg orally every 3 days, then move to 1.5 mg orally every other day if warranted, guided by clinical response and tolerability. For patients on a strong CYP3A4 inhibitor who are being treated for bipolar depression or as adjunctive therapy for major depressive disorder (MDD), the dose should be 1.5 mg orally every 3 days. When a strong CYP3A4 inhibitor is added to a stable cariprazine regimen, the cariprazine dose must be modified: patients currently taking 1.5 or 3 mg once daily should be switched to 1.5 mg orally every 3 days upon starting the inhibitor, while those currently taking 4.5 or 6 mg once daily should be switched to 1.5 mg orally every other day. If the strong CYP3A4 inhibitor is later stopped, the cariprazine dose may require an increase according to clinical response and tolerability. In addition, using cariprazine (a CYP3A4 substrate) together with a CYP3A4 inducer is not recommended. The formation and elimination of cariprazine's active metabolites depend on CYP3A4. Because the influence of CYP3A4 inducers on cariprazine exposure has not been studied, the overall effect remains unclear1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediate cariprazine metabolism; induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
Keep taking both medicines exactly as prescribed. The key here is that cariprazine's dose is deliberately lowered and spaced out when it is combined with a strong CYP3A4 inhibitor like telaprevir, so the drug does not accumulate.
- Make sure both your prescriber and pharmacist have both drugs on your list.
- Your team may start or adjust cariprazine to a lower, less frequent dose (for example, taken every 3 days or every other day) and individualize it based on how you respond and tolerate it.
- If telaprevir is later stopped, your cariprazine dose may need to be raised again.
- Report new restlessness, stiffness, tremor, or heavy drowsiness.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In drug interaction studies, giving cariprazine 0.5 mg/day together with ketoconazole (a strong CYP3A4 inhibitor) 400 mg/day led to an increase in total cariprazine AUC and Cmax of approximately 100% 1.
Common questions
Can I take Telaprevir and Cariprazine together?
Telaprevir can raise cariprazine levels and side effects by blocking the enzyme that clears it, so your care team will use a lower, less frequent cariprazine dose and monitor you. Do not adjust doses yourself; confirm the plan with your pharmacist or prescriber. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Telaprevir and Cariprazine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Telaprevir and Cariprazine interaction managed?
Keep taking both medicines exactly as prescribed. The key here is that cariprazine's dose is deliberately lowered and spaced out when it is combined with a strong CYP3A4 inhibitor like telaprevir, so the drug does not accumulate. Make sure both your prescriber and pharmacist have both drugs on your list. Your team may start or adjust cariprazine to a lower, less frequent dose (for example, taken e… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Telaprevir or Cariprazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Telaprevir
Keep reading about Cariprazine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist